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The ¿ rst known Ebola hemorrhagic fever (EHF) out-
break caused by Bundibugyo Ebola virus occurred in 
Bundibugyo District, Uganda, in 2007. Fifty-six cases of 
EHF were laboratory con¿ rmed. Although signs and symp-
toms were largely nonspeci¿ c and similar to those of EHF 
outbreaks caused by Zaire and Sudan Ebola viruses, pro-
portion of deaths among those infected was lower (|40%). 
Ebola hemorrhagic fever (EHF) is a severe disease caused by several species of Ebolavirus (EBOV), 
in the family Filoviridae. Before 2007, four species of 
EBOV had been identi¿ ed; 2 of these, Zaire ebolavirus 
and Sudan ebolavirus, have caused large human outbreaks 
in Africa, with proportion of deaths |80%–90% and 50%, 
respectively (1–5). Large outbreaks are associated with 
person-to-person transmission after the virus is introduced 
into humans from a zoonotic reservoir. Data suggest that 
this reservoir may be fruit bats (6,7). During outbreaks of 
EHF, the virus is commonly transmitted through direct 
contact with infected persons or their bodily À uids (8–11). 
The onset of EHF is associated with nonspeci¿ c signs and 
symptoms, including fever, myalgias, headache, abdomi-
nal pain, nausea, vomiting, and diarrhea; at later stages of 
disease, overt hemorrhage has been reported in |45% of 
cases (12).
Bundibugyo District is located in western Uganda, 
which borders the Democratic Republic of Congo. After 
reports of a mysterious illness in Bundibugyo District, the 
presence of a novel, ¿ fth EBOV virus species, Bundibugyo 
ebolavirus (BEBOV), was identi¿ ed in diagnostic samples 
submitted to the Centers for Disease Control and Prevention 
(CDC), Atlanta, Georgia, USA, in November 2007 (13). In 
response to detection of EBOV, an international outbreak 
response was initiated. In this report, we summarize ¿ nd-
ings of laboratory-con¿ rmed cases of BEBOV infection.
The Study
Anecdotal reports suggested that human illness con-
sistent with a viral hemorrhagic fever arose in Bundibugyo 
District as early as August 2007. After EHF was con¿ rmed 
(13), isolation wards were established at 2 medical facili-
ties in the district. Diagnostic samples from hospitalized 
patients with acute illness and community residents who 
had febrile illnesses and multiple additional signs, symp-
toms, or epidemiologic exposures suggestive of EHF, were 
routinely collected for EBOV testing. These signs and 
symptoms included headache, vomiting, diarrhea, abdomi-
nal pain, conjunctivitis, skin rash, muscle pain, fatigue, dif-
¿ culty swallowing, dif¿ culty breathing, hiccups, bleeding, 
unexplained death, or contact with a patient with suspected 
EHF. A laboratory-con¿ rmed case of EHF was de¿ ned as 
illness in a person whose diagnostic samples were found 
positive for EBOV infection by any of the following tests: 
PCR (13), virus isolation, antigen detection, or immuno-
globulin (Ig) M ELISA (14,15).
In addition, in a subset of surviving persons who had 
a history of illness consistent with EHF but no acute-phase 
blood samples available for testing, a convalescent-phase 
blood sample was collected for laboratory con¿ rmation by 
IgG ELISA (14, 15). Laboratory testing was performed at 
the Uganda Viral Research Institute in Entebbe, and subse-
quent testing was performed on some samples at CDC, At-
lanta. This analysis is limited to laboratory-con¿ rmed EHF 
cases, although additional suspected cases were identi¿ ed 
during the outbreak.
Fifty-six con¿ rmed cases of EHF were identi¿ ed; 43 
of these were diagnosed on the basis of positive test results 
from acute-phase specimens (Figure). Twenty-six patients 
had a positive EBOV IgG titer in convalescent-phase se-
rum, including 13 persons who had evidence of EBOV in-
fection in acute-phase and convalescent-phase samples.
The proportion of deaths during this outbreak was 
calculated for case-patients con¿ rmed on the basis of an 
acute-phase diagnostic sample (those who only had a con-
valescent-phase sample are by de¿ nition surviving case-
patients and represent a biased sample). Of the 43 cases 
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con¿ rmed from acute-phase samples, 17 deaths occurred, 
for a proportion of 40%. The mean age of those who died 
(42 years, range 20–70 years) was signi¿ cantly higher than 
that of survivors (33 years, range 12–50 years; p = 0.0390). 
No gender bias was observed between survivors and those 
who died (Table).
Signs and symptoms were reported by patients on 
standardized surveillance case-report forms at the time of 
case identi¿ cation, and in some instances, were examined 
further by chart review or follow-up interview. Common 
symptoms among patients with laboratory-con¿ rmed cases 
included fever, fatigue, headache, nausea/vomiting, abdom-
inal pain, muscle/joint pain, diarrhea, and anorexia/weight 
loss (Table). No difference in the proportion of those re-
porting signs and symptom between those who survived 
and those who died was noted, except for dif¿ culty swal-
lowing. This symptom was more common among case-pa-
tients who died (though marginally signi¿ cant, p = 0.0851). 
Bleeding of any type (bleeding from injection site, gums, 
eyes, nose, vagina; black or bloody stool; bloody vomitus; 
or hematuria) was reported among 54% of all patients with 
laboratory-con¿ rmed cases.
As part of the standardized surveillance case-report 
form, patients were also asked whether they had had con-
tact with a sick person during the 3 weeks before develop-
ment of illness. A large portion of the laboratory-con¿ rmed 
case-patients in this outbreak reported direct contact with a 
speci¿ c person, (case X), who died of a severe hemorrhagic 
febrile illness consistent with EHF (no diagnostic speci-
mens were collected from this person) in November 2007. 
Using the date of last contact for those reporting contact 
with case X or reporting contact with another laboratory-
con¿ rmed case-patient to the date of symptom onset, we 
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Figure. Number of laboratory-con¿ rmed Ebola hemorrhagic fever 
(EHF) cases diagnosed on the basis of positive acute-phase 
or convalescent-phase diagnostic samples and calculation of 
proportion of deaths among case-patients who had an acute-phase 
diagnostic sample, Bundibugyo District, Uganda, 2007.
Table. Demographic characteristics and signs and symptoms for 56 case-patients who had laboratory-confirmed EHF, Bundibugyo 
District, Uganda, in 2007* 
Characteristic
Case-patients confirmed by acute-phase sample, n = 43 Total no. confirmed 
case-patients, n = 56 No. survived, n = 26 No. died, n = 17 p value 
Mean age, y (range) 33 (12–50) 42(20–70) 0.039† 37.4 (11–70) 
Male sex (%) 16 (62) 8 (47) >0.100‡ 30 (54) 
Mean incubation period, d (95% CI)§ 5.7 (4.4–7.0) 7.4 (5.4–9.3) >0.100† 6.3 (5.2–7.3) 
Signs and symptoms, no. reporting/no. available (%)¶ 
Fever 26/26 (100) 16/16 (100) >0.100 55/55 (100) 
Fatigue 22/23 (96) 14/14 (100) >0.100 49/50 (98) 
Headache 21/25 (84) 14/15 (93) >0.100 48/53 (91) 
Nausea/vomiting 24/26 (92) 13/15 (87) >0.100 48/54 (89) 
Abdominal pain 23/26 (88) 13/14 (93) >0.100 47/53 (89) 
Muscle/joint pain 19/23 (83) 12/14 (86) >0.100 44/50 (88) 
Diarrhea 24/26 (92) 13/15 (87) >0.100 47/54 (87) 
Anorexia/weight loss 19/23 (83) 12/15 (80) >0.100 43/51 (84) 
Difficulty swallowing 10/23 (43) 6/15 (60) >0.100 27/51 (53) 
Rash 9/26 (35) 5/15 (33) >0.100 25/54 (46) 
Difficulty breathing 6/23 (26) 8/14 (57) 0.085 23/50 (46) 
Hiccups 4/23 (17) 6/15 (40) >0.100 16/51 (31) 
Bleeding# 11/26 (42) 9/17 (53) >0.100 30/56 (54) 
*EHF, Ebola hemorrhagic fever; CI, confidence interval. 
†By 2-sample t-test. 
‡By F2 test. 
§For case-patients reporting contact with a confirmed case-patient, or contact with case-patient X (see text for full description), based on time from last 
reported contact with case-patient to development of signs and symptoms (n = 16 for case-patients in Survived column; n = 8 for case-patients in Died 
column; n = 24 for all confirmed case-patients). 
¶No. case-patients reporting the sign or symptom/no. case-patients with information available about presence of that the sign or symptom. p value was 
determined by Fisher exact test in which a comparison was made between the proportion of case-patients who survived vs. those who died. 
#At least 1 of the following manifestations: bleeding from injection site, gums, eyes, nose, vagina; black or bloody stool; bloody vomitus; hematuria. 
Bundibugyo Ebola Virus, Uganda
calculated an average incubation period of 6.3 days among 
laboratory-con¿ rmed EHF case-patients (n = 24). No sig-
ni¿ cant difference was noted in the incubation period be-
tween survivors (5.7 days) and those who died (7.4 days).
Conclusions
The 2007 outbreak of EHF in Bundibugyo District, 
Uganda, was caused by a new EBOV species, Bundibu-
gyo ebolavirus (13). Previous outbreaks of EHF have re-
sulted in high proportion of deaths, ranging from 50% to 
90% (1–5). The proportion of deaths among case-patients 
with EHF con¿ rmed by acute diagnostic specimens in this 
outbreak was 40%, a lower percentage than for other spe-
cies of EBOV that have caused human outbreaks in Africa. 
However, we cannot exclude the possibility that the lower 
proportion of deaths in this outbreak is an artifact of dif-
ferences in the severity of laboratory-con¿ rmed cases de-
tected through outbreak surveillance or the quality of care 
received by hospitalized laboratory-con¿ rmed EHF case-
patients in Bundibugyo District. Nonetheless, sustained 
person-to-person transmission was suf¿ cient to result in a 
sizeable outbreak, and death was clearly not uncommon. 
Thus, BEBOV should be considered a pathogen of serious 
public health concern.
As with previously documented EHF outbreaks, older 
age appeared to be a risk factor for death (3). The incuba-
tion period of EHF was |1 week, and signs and symptoms 
were largely nonspeci¿ c; infections frequently involved 
fever, fatigue, headache, gastrointestinal involvement, and 
muscle and joint pain. The nonspeci¿ c nature of these signs 
and symptoms, which may mimic other tropical diseases, 
made diagnosis of EHF based on clinical characteristics 
alone particularly challenging and underscores the im-
portance of laboratory-based diagnostics to con¿ rm and 
monitor control and response efforts for EHF outbreaks. 
Notably, signs and symptoms described in this report are 
primarily based on information from patient surveillance 
case-report forms ¿ lled out at the time of triage, and they 
may not represent the full spectrum of illness experienced 
by all persons with EHF during this outbreak.
It is apparent that novel emerging infections contin-
ue to occur. The outbreak of EHF described in this report 
involved a previously unidenti¿ ed EBOV species, with a 
proportion of deaths of 40%. BEBOV represents the fourth 
EBOV species–associated disease in humans, and the third 
species to cause large human outbreaks of EHF. Although 
proportion of deaths was lower than that documented in 
previous EHF outbreaks, BEBOV is a severe human patho-
gen with epidemic potential. These ¿ ndings demonstrate 
the need for increased surveillance and diagnostic capabili-
ties, as well as the capacity to respond quickly to emerging 
human infections. 
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